Nosocomial Outbreak of BHRe in an Intensive Care Unit During SARS-CoV-2 Pandemic

NCT05055479 | Completed

• 1 other identifier: PI2021_843_0187
• Study Type: observational
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

Multidrug Resistant (MDR) bacteria have become a major worldwide public health challenge and hospitals are now increasingly faced with management of local outbreaks involving such pathogens. Especially, intensive care units (ICU) provide an ideal background for outbreaks caused by MDR bacteria among which carbapenemase-producing Enterobacteriaceae (CPE) can be found. Among CPE involved in ICU outbreaks, VIM producers have been reported worldwide, and described as especially difficult to control. The COVID-19 pandemic and all of the measures health workers have to implement to fight the spread of SARS-Cov-2 have also impacted the management of such outbreaks. In this retrospective study, the investigators aim to describe the management of an outbreak caused by a VIM-producing Enterobacter cloacae strain during the 2020 COVID-19 pandemic in an ICU, and show the importance of concerted measures and actions implemented at multiple levels to prevent the spread of this MDR strain.

Conditions

Enterobacteriaceae Infections; Hospital-Acquired Infection

Keywords

outbreak; Enterobacteriaceae Infections; Hospital-Acquired Infection; integrated approach; VIM

Outcome Measures

Primary Outcomes (1)

• Change in care type of BHRe in ICU

  Management of VIM-producing Enterobacter cloacae strain care in ICU. All types of therapeutics used to manage atrial fibrillation are collected

  1 month

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients who have stayed in ICU and with positive sample to E. cloacae VIM between March and October 2020.

You may qualify if:

• patients who have stayed in ICU
• patients with positive sample to E. cloacae VIM between March and October 2020

You may not qualify if:

• patients who didn't agreed to be included

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHU Amiens Picardie

Amiens, Picardie, 80054, France

Location

Related Publications (1)

• Mullie C, Lemonnier D, Adjide CC, Maizel J, Mismacque G, Cappe A, Carles T, Pierson-Marchandise M, Zerbib Y. Nosocomial outbreak of monoclonal VIM carbapenemase-producing Enterobacter cloacae complex in an intensive care unit during the COVID-19 pandemic: an integrated approach. J Hosp Infect. 2022 Feb;120:48-56. doi: 10.1016/j.jhin.2021.11.017. Epub 2021 Nov 30.

  PMID: 34861315 RESULT

MeSH Terms

Conditions

Enterobacteriaceae Infections; Cross Infection

Condition Hierarchy (Ancestors)

Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Iatrogenic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 15, 2021
• First Posted: September 24, 2021
• Study Start: August 1, 2021
• Primary Completion: January 1, 2022
• Study Completion: February 1, 2022
• Last Updated: November 19, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)